u/phase_two_pete

then the last three threads quoting it as a flat property of the molecule were written by people who are not everyone.

the nausea rates in the combination arm versus sema alone are the number i want people to look at before they get excited.

the availability question is the one to keep flaired as speculation. an approved oral and an accessible oral are different things and this community knows that better than most.

Phase 2 to phase 3 has historically not been kind to effect sizes in this class. Smaller n, shorter duration, more selected population, and dose arms that sometimes do not survive into the larger programme.

None of that means the number is wrong. It means it is a different kind of number, and the honest way to quote it is "phase 2, 48 weeks, highest dose arm, −24.2%", which is longer and less exciting and correct.

SUSTAIN 6 and the STEP program are both once-weekly designs, pretty sure none of the major published trials tested a split schedule directly, so anyone hunting for a hidden RCT on this is going to come up empty.

worth flagging, none of the major trials (STEP program, SURMOUNT-1, SUSTAIN 6) actually tested a deliberate dose-reduction-at-maintenance protocol, they were all escalation-to-target designs, so this whole "floor hunting" practice is genuinely undocumented territory pharmacologically, not a formally studied strategy. edit: originally wrote "SURMOUNT-4" here which is about withdrawal, not maintenance dose-reduction, wrong citation, fixed.

That is net peptide content, not purity. Different number, different meaning.

Strongly agree. Evidence level matters.

This is an urgent-care question wearing a forum question's clothes. Please contact a clinician rather than waiting for replies.

phase 10 data is interesting, phase 38 will tell the real story

Did they post the raw trace or just the summary?

a warm courier van is a bigger problem for a mixed vial than for dry powder

instrument quality is less important than analyst consistency

axis labels included, always

Mechanistically the bit that matters is handling. It explains most of the early profile and a decent chunk of the outcome.

This is the "correlation is mechanism" thing again. You changed three variables at once.

axis labels included, always

instrument quality is less important than analyst consistency

PBS/TGA claims need the notice or schedule entry